Market Overview

Canaccord Genuity Reiterates Buy Rating, $11 PT on Raptor Pharmaceutical

Share:
Related RPTP
Benzinga's Top Downgrades
Benzinga's M&A Chatter for Monday September 12, 2016
Horizon Pharma: Another Core Plus Biotech Worth Buying (Seeking Alpha)

In a report published Wednesday, Canaccord Genuity reiterated its Buy rating and $11.00 price target on Raptor Pharmaceutical (NASDAQ: RPTP).

Canaccord Genuity noted, “Reiterate BUY, $11 target on high chance of PROCYSBI H1/13 US and 2014 EU approval/launch. We expect PROCYSBI to be approved in the US (March 30 PDUFA) and EU, with H1/13 and 2014 launches, respectively. We predict manageable payor pushback on premium orphan pricing and quick adoption. Our $11 target is based on a pNPV analysis.”

Raptor Pharmaceutical closed on Monday at $5.39.

Latest Ratings for RPTP

DateFirmActionFromTo
Sep 2016Cowen & Co.DowngradesOutperformMarket Perform
Aug 2016CitigroupMaintainsNeutral
Aug 2016CitigroupDowngradesBuyNeutral

View More Analyst Ratings for RPTP
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Reiteration Analyst Ratings

 

Related Articles (RPTP)

View Comments and Join the Discussion!